Physician underutilization of effective medications for resistant hypertension at office visits in the United States: NAMCS 2006-2010

Journal of General Internal Medicine

Volumn 29, Issue 3, 2014, Pages 468-476

  Fontil, Valy ^a,c   Pletcher, Mark J ^a   Khanna, Raman ^a   Guzman, David ^a,c   Victor, Ronald ^b   Bibbins Domingo, Kirsten ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

chlorthalidone; fixed dose combination; guidelines adherence; hypertension management; medication use; resistant hypertension; spironolactone

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ADULT; AGE; AGED; AMBULATORY CARE; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOLOGIST; COMORBIDITY; CROSS-SECTIONAL STUDY; DRUG USE; FEMALE; GENERAL PRACTITIONER; GEOGRAPHY; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; INTERNIST; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PATIENT CARE; PRACTICE GUIDELINE; PRESCRIPTION; PROTOCOL COMPLIANCE; PUBLICATION; RESISTANT HYPERTENSION; SPECIALIZATION; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OFFICE VISITS; PHYSICIAN'S ROLE; TREATMENT OUTCOME; UNITED STATES;

EID: 84896728229     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-013-2683-y     Document Type: Article

References (46)

1. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation. 2012;125(13):1594-6.
2. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57(6):1076-80.
3. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510-26.
4. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635-42.
5. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16(11 Pt 1):925-30.
6. Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens. 2002;15(4 Pt 1):333-9.
7. Vaclavik J, Sedlak R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57(6):1069-75.
8. Vlase HL, Panagopoulos G, Michelis MF. Effectiveness of furosemide in uncontrolled hypertension in the elderly: role of renin profiling. Am J Hypertens. 2003;16(3):187-93.
9. Sica DA. Chlorthalidone: has it always been the best thiazide-type diuretic? Hypertension. 2006;47(3):321-2.
10. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47(3):352-8.
11. National Ambulatory Medical Care Survey. Ambulatory Health Care Data. Available at: http://www.cdc.gov/nchs/ahcd/about-ahcd.htm. Accessed October 08, 2013.
12. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219.
13. NAMCS Survey Instruments. Ambulatory Health Care Data. Available at: http://www.cdc.gov/nchs/ahcd/ahcd-survey-instruments.htm#namcs. Accessed October 08, 2013.
14. NAMCS Scope and Sample Design. Ambulatory Health Care Data Available at: http://www.cdc.gov/nchs/ahcd/ahcd-scope.htm#namcs-scope. Accessed October 08, 2013.
15. NAMCS Data Collection and Processing. Ambulatory Health Care Data. Available at: http://www.cdc.gov/nchs/ahcd/ahcd-data-collection.htm#namcs- collection Accessed October 08, 2013.
16. NAMCS Estimation Procedures. Ambulatory Health Care Data. Available at: http://www.cdc.gov/nchs/ahcd/ahcd-estimation-procedures.htm#namcs-procedures. Accessed October 08, 2013.
17. Reliability of Estimates. Ambulatory Health Care Data. Available at: http://www.cdc.gov/nchs/ahcd/ahcd-estimation-reliability.htm. Accessed October 08, 2013.
18. National Drug Code Directory. Available at: http://www.fda.gov/Drugs/ InformationOnDrugs/ucm142438.htm Accessed October 08, 2013.
19. Mancia G, Bombelli M, Seravalle G, Grassi G. Diagnosis and management of patients with white-coat and masked hypertension. Nat Rev Cardiol. 2011;8(12):686-93.
20. Hanselin MR, Saseen JJ, Allen RR, Marrs JC, Nair KV. Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. Hypertension. 2011;58(6):1008-13.
21. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ. 1999;160(1):41-6.
22. Patel BV, Remigio-Baker RA, Mehta D, Thiebaud P, Frech-Tamas F, Preblick R. Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States. J Clin Hypertens (Greenwich). 2007;9(9):692-700.
23. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-72.
24. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9):1046-58.
25. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825-34.
26. Basile J, Neutel J. Overcoming clinical inertia to achieve blood pressure goals: the role of fixed-dose combination therapy. Ther Adv Cardiovasc Dis. 2010;4(2):119-27.
27. Basile J, Black HR, Flack JM, Izzo JL Jr. The role of therapeutic inertia and the use of fixed-dose combination therapy in the management of hypertension. J Clin Hypertens (Greenwich). 2007;9(8):636-45.
28. Cushman WC, Basile J. Achieving blood pressure goals: why aren't we? J Clin Hypertens (Greenwich). 2006;8(12):865-72.
29. Andrade SE, Gurwitz JH, Field TS, et al. Hypertension management: the care gap between clinical guidelines and clinical practice. Am J Manag Care. 2004;10(7 Pt 2):481-6.
30. Ashton CM, Khan MM, Johnson ML, et al. A quasi-experimental test of an intervention to increase the use of thiazide-based treatment regimens for people with hypertension. Implement Sci. 2007;2:5.
31. Clark D 3rd, Ahmed MI, Calhoun DA. Resistant hypertension and aldosterone: an update. Can J Cardiol. 2012;28(3):318-25.
32. Epstein M, Calhoun DA. Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. J Clin Hypertens (Greenwich). 2011;13(9):644-8.
33. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004;43(1):4-9.
34. Grimshaw J, Eccles M, Thomas R, et al. Toward evidence-based quality improvement. Evidence (and its limitations) of the effectiveness of guideline dissemination and implementation strategies 1966-1998. J Gen Intern Med. 2006;21(Suppl 2):S14-20.
35. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003;41(1):56-61.
36. Siegel D. The influence of national guidelines on antihypertensive prescribing patterns. Curr Hypertens Rep. 2000;2(3):247-52.
37. Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013;310(7):699-705.
38. Stewart S, Carrington MJ, Swemmer CH, et al. Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial. BMJ. 2012;345:e7156.
39. Glynn LG, Murphy AW, Smith SM, Schroeder K, Fahey T. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2010;3, CD005182.
40. Guidelines for the Management of Hypertension. 2005; Available at: http://www.permanente.net/healthyheart/resources/tools/KP%20CPG%20Hypertension. pdf. Accessed October 08, 2013.
41. Hypertension Clinical Practice Guidelines. KAISER PERMANENTE NATIONAL CLINICAL PRACTICE GUIDELINES. 2009; Available at: http://www.delfini.org/ KP%20BP/2009-Hypertension-Guidelines-Public.pdf Accessed October 08, 2013.
42. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR, Service RUH. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens. 2005;18(5 Pt 1):619-26.
43. Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med. 1991;151(9):1786-92.
44. Paulis L, Steckelings UM, Unger T. Key advances in antihypertensive treatment. Nat Rev Cardiol. 2012;9(5):276-85.
45. Better technology shows that too many people are treated for high blood pressure. 2013; Available at: http://articles.washingtonpost.com/2013-06-03/ national/39709940-1-have-hypertension-67-million-americans. Accessed October 08, 2013.
46. Ruilope LM. Current challenges in the clinical management of hypertension. Nat Rev Cardiol. 2012;9(5):267-75.